The disclosure is based, at least in part, on certain human monoclonal antibodies, or antigen binding fragments thereof, having unexpected broad neutralizing activities against SARS – CoV – 2. The disclosed antibodies and/or antigen-binding fragments thereof are therapeutic agents for the treatment of SARS – CoV – 2 infections and are suitable for use in therapeutic methods to protect individuals from SARS – CoV – 2 infections.
Date of Application
March 9, 2021
James Kobie, Mark R. Walter, Michael Piepenbrink, Ashlesha Deshpande, Paul Gopefert, Nathaniel Erdmann, and Luis Martinez-Sobrido